Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pan...

詳細記述

保存先:
書誌詳細
出版年:J Immunother
主要な著者: Royal, Richard E., Levy, Catherine, Turner, Keli, Mathur, Aarti, Hughes, Marybeth, Kammula, Udai S., Sherry, Richard M., Topalian, Suzanne L., Yang, James C., Lowy, Israel, Rosenberg, Steven A.
フォーマット: Artigo
言語:Inglês
出版事項: 2010
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322622/
https://ncbi.nlm.nih.gov/pubmed/20842054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181eec14c
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料